ArticleFrontiers in oncology2025
Global, regional, and national metabolic risk factors associated with multiple myeloma, 1990-2021: analysis via the global burden of disease study 2021.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: This study aimed to examine the global disease burden of multiple myeloma (MM) linked to metabolic factors. Using data from GHDx spanning 1990-2021, MM cases were identified via ICD-10 codes (C90.0). Key metrics, including mortality rate and disability-adjusted life years (DALYs) rate, were analyzed; age-standardized rates (ASMR, ASDR) and estimated annual percentage change (EAPC) were computed using R to compare disparities across regions, genders, and age groups. Methods and data sources: Thirty-one years of data from GHDx were utilized to capture temporal trends. MM cases were coded according to ICD-10 (C90.0), and age-standardized rates were applied to reduce demographic biases. Temporal changes were assessed via EAPC, while differences across regions, genders, and age groups were analyzed through comparisons of ASMR and ASDR. Key findings: From 1990 to 2021, global deaths from metabolic-related MM tripled, with DALYs increasing by 2.8 times. Mortality rates, ASMR, and ASDR showed significant upward trends-slowing between 2000 and 2010 before rebounding. Males exhibited higher ASDR and ASMR, attributed to lifestyle factors and estrogen-mediated protection in females. Middle-SDI countries saw sharp increases in ASDR (driven by population aging and limited healthcare access), whereas High-SDI countries exhibited slower growth (due to advanced treatment options). Most regions recorded rising ASDR, except in high-income Asia Pacific and North America (attributed to novel therapeutic agents). The United States, China, and Germany recorded the highest number of deaths (linked to population size and aging), while countries such as the Bahamas had elevated rates. Underdeveloped regions grappled with underdiagnosis problems. Age-specific analysis showed a rising burden among those aged 70-74 years and older, with elderly males being the most affected group in 2021. Conclusions: The global burden of metabolic-related MM is shaped by demographic factors, economic conditions, lifestyle, and healthcare provision. High-risk groups (elderly males, Middle-SDI countries, and regions with poor metabolic health) necessitate tailored, region-specific prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.